Angiotensin II upregulates endothelial lipase expression via the NF-kappa B and MAPK signaling pathways

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Zhang, Xiaoli ^a   Wu, Minghui ^b   Jiang, Hong ^b   Hao, Jing ^a   Zhang, Qingli ^c   Zhu, Qing ^b   Saren, Gaowa ^b   Zhang, Yun ^b   Meng, Xiaohui ^c   Yue, Xin ^b  

^a SHANDONG UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CYCLINE; ENDOTHELIAL LIPASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ENZYME INHIBITOR; IMIDAZOLE DERIVATIVE; LIPG PROTEIN, HUMAN; PYRIDINE DERIVATIVE; PYRROLIDINE DERIVATIVE; PYRROLIDINE DITHIOCARBAMIC ACID; THIOCARBAMIC ACID DERIVATIVE;

ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME PHOSPHORYLATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UMBILICAL VEIN ENDOTHELIAL CELL; UPREGULATION; WESTERN BLOTTING; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; METABOLISM; TIME;

ANGIOTENSIN II; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; ENZYME INHIBITORS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMIDAZOLES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; LIPASE; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, FLUORESCENCE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; PYRROLIDINES; THIOCARBAMATES; TIME FACTORS; TRANSCRIPTION FACTOR RELA;

EID: 84907574430     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107634     Document Type: Article

References (52)

1. Halkin A, Keren G. (2002) Potential indications for angiotensin-converting enzyme inhibitors in atherosclerotic vascular disease. Am J Med 112: 126-134.
2. Weiss D, Kools JJ, Taylor W.R. (2001) Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation 103: 448-454.
3. Daugherty A, Manning MW, Cassis L.A. (2000) Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 105: 1605-1612.
4. Dol F, Martin G, Staels B., Mares AM, Cazaubon C, et al. (2001) Angiotensin AT1 receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 38: 395-405.
5. Nishimura H, Tsuji H, Masuda H., Nakagawa K, Nakahara Y, et al (1997) Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 77: 1189-1195.
6. van Leeuwen R.T., Kol A, Andreotti F., Kluft C, Maseri A, et al (1994) Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation 90: 362-368.
7. Wilson HM, Haites NE, Booth NA (1997) Effect of angiotensin II on plasminogen activator inhibitor-1 production by cultured human mesangial cells. Nephron 77: 197-204.
8. Ridker PM, Gaboury CL, Conlin P.R., Seely EW, Williams GH et al. (1993) Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87: 1969-1973.
9. Nishimura H, Tsuji H, Masuda H., Kasahara T, Yoshizumi M, et al (1999) The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells. Thromb Haemost 82: 1516-1521.
10. Larsson PT, Schwieler JH, Wallen N.H. (2000) Platelet activation during angiotensin II infusion in healthy volunteers. Blood Coagul Fibrinolysis 11: 61-69.
11. Poplawski A (1970) The effect of angiotensin II on the platelet aggregation induced by adenosine diphosphate, epinephrine and thrombin. Experientia. 26: 86.
12. Ding YA, MacIntyre DE, Kenyon C.J., Semple P.F. (1985) Potentiation of adrenaline-induced platelet aggregation by angiotensin II. Thromb Haemost 54: 717-720.
13. Swartz SL, Moore T.J. (1990) Effect of angiotensin II on collagen-induced platelet activation in normotensive subjects. Thromb Haemost 63: 87-90.
14. Jagroop IA, Mikhailidis D.P. (2000) Angiotensin II can induce and potentiate shape change in human platelets: effect of losartan. J Hum Hypertens 14: 581-585.
15. Mogielnicki A, Chabielska E, Pawlak R., Szemraj J, Buczko W. (2005) Angiotensin II enhances thrombosis development in renovascular hypertensive rats. Thromb Haemost 93: 1069-1076.
16. Mazzolai L, Hayoz D. (2006) The renin-angiotensin system and atherosclerosis. Curr Hypertens Rep 8: 47-53.
17. Brasier AR, Recinos A 3rd, Eledrisi MS (2002) Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 22: 1257-1266.
18. Daugherty A, Cassis L. (2004) Angiotensin II-mediated development of vascular diseases. Trends Cardiovasc Med 14: 117-120.
19. Daugherty A, Rateri DL, Lu H, Inagami T., Cassis L.A. (2004) Hypercholester-olemia stimulates angiotensin peptide synthesis and contributes to atherosclerosis through the AT1A receptor. Circulation 110: 3849-3857.
20. Jaye M, Lynch KJ, Krawiec J, Marchadier D., Maugeais C, et al. (1999) A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 21: 424-428.
21. Broedl UC, Maugeais C, Millar J.S., Jin W., Moore RE, et al. (2004) Endothelial lipase promotes the catabolism of ApoB-containing lipoproteins. Circ Res 94: 1554-1561.
22. Ishida T, Choi SY, Kundu R.K., Spin J., Yamashita T, et al. (2004) Endothelial lipase modulates susceptibility to atherosclerosis in apolipoprotein-E-deficient mice. J Biol Chem 279: 45085-45092.
23. Jin W, Sun GS, Marchadier D, Octtaviani E., Glick JM, et al. (2003) Endothelial cells secrete triglyceride lipase and phospholipase activities in response to cytokines as a result of endothelial lipase. Circ Res 92: 644-650.
24. Choi SY, Hirata K, Ishida T., Quertermous T, Cooper A.D. (2002) Endothelial lipase: a new lipase on the block. J Lipid Res 43: 1763-1769.
25. Gilmore TD (2006) "Introduction to NF-kB: players, pathways, perspectives". Oncogene 25: 6680-4.
26. Brasier AR (2006) "The NF-kB regulatory network". Cardiovasc Toxicol 6: 111-30.
27. Perkins ND (2007) "Integrating cell-signalling pathways with NF-kB and IKK function". Nat Rev Mol Cell Biol 8: 49-62.
28. Gilmore TD (1999) "The Rel/NF-kB signal transduction pathway: introduction". Oncogene 18: 6842-4.
29. Tian B, Brasier A.R. (2003) "Identification of a nuclear factor k B-dependent gene network". Recent Prog Horm Res 58: 95-130.
30. Monaco C, Andreakos E, Kiriakidis S. (2004) "Canonical pathway of nuclear factor kappa B activation selectively regulates proinflammatory and prothrom-botic responses in human atherosclerosis". Proc Natl Acad Sci 101: 5634-9.
31. Han J, Lee JD, Bibbs L, Ulevitch R.J. (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 565: 808-811.
32. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, et al (2001). "Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions". Endocr Rev 22: 153-83.
33. Goldstein DM, Gabriel T. (2005) Pathway to the clinic: inhibition of p38 MAP kinase. A review of ten chemotypes selected for development. Curr Top Med Chem 5: 1017-1029.
34. Hirata K, Ishida T, Matsushita H., Tsao PS, Quertermous T. (2000) Regulated expression of endothelial cell-derived lipase. Biochem Biophys Res Commun. 272: 90-93.
35. Annema W, Tietge U.J. (2005) Role of hepatic lipase and endothelial lipase in high-density lipoprotein-mediated reverse cholesterol transport. Nat Rev Drug Discov 4: 193-205.
36. Badellino KO, Wolfe ML, Rielly M.P., Rader D.J. (2006) Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis. PLoS Med 3: 0245-0252.
37. Fang YQ, Huang L, Li A.M., Song YM, Jin J, et al. (2007) Significance of the ratio of circulating endothelial cell expressing endothelial lipase and supersen-sitivity C-reactive protein in prognosis of patients with coronary artery disease. 19: 644-646.
38. Cai G, He G, Qi C. (2012) The association between endothelial lipase 2384A/C gene polymorphism and acute coronary syndrome in a Chinese population. Mol Biol Rep 39: 9879-9884.
39. Singaraja RR, Sivapalaratnam S, Hovingh K., Dubé MP, Castro-Perez J, et al. (2013) The Impact of Partial and Complete Loss of Function Mutations in Endothelial Lipase on HDL Levels and Functionality in Humans. Circ Cardiovasc Genet 6: 54-62.
40. Badellino KO, Wolfe ML, Reilly M.P., Rader D.J. (2008) Endothelial lipase is increased in vivo by inflammation in humans. Circulation 117: 678-685.
41. Paradis ME, Badellino KO, Rader D.J., Deshaies Y., Couture P, et al. (2006) Endothelial lipase is associated with inflammation in humans. Lipid Res 47: 2808-2813.
42. Jiang Y, Kohara K, Hiwada K. (2000) Association between risk factors for atherosclerosis and mechanical forces in carotid artery. Stroke 31: 2319-2324.
43. Ma T, Pan Q, Zhu Q., Ren P. (2006) Effects of Atorvastatin on Proliferation and mRNA Expression of Endothelial Lipase in Cultured Human Umbilical Vein Endothelial Cells. Chinese Journal of Arteriosclerosis 06: 471-474.
44. Pueyo ME, Gonzaez W, Nicoletti A., Savoie F, Arnal JF, et al (2000) Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscl Thromb Vasc Biol 20: 45-651.
45. Kempe S, Kestler H, Lasar A., Wirth T. (2005) NF-kappaB controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program. Nucleic Acids Res 33: 5308-5319.
46. Yogi A, Callera GE, Aranha A.B., Antunes TT, Graham D, et al. (2011) Sphingosine-1-phosphate-induced inflammation involves receptor tyrosine kinase transactivation in vascular cells: upregulation in hypertension. Hypertension 57: 809-818.
47. Gerthoffer WT (2007) Mechanisms of vascular smooth muscle cell migration. Circ Res 100: 607-621.
48. Jacobsen JC, Mulvany MJ, Holstein-Rathlou NH (2008) A mechanism for arteriolar remodeling based on maintenance of smooth muscle cell activation. Am J Physiol Regul Integr Comp Physiol 294: R1379-R1389.
49. Schiffrin EL, Touyz R.M. (2004) From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension. Am J Physiol Heart Circ Physiol. 287: H435-H446.
50. Paravicini TM, Montezano AC, Yusuf H, Touyz R.M. (2012) Activation of vascular p38 MAPK by mechanical stretch is independent of c-Src and NADPH oxidase: influence of hypertension and angiotensin II. J Am Soc Hypertension 6: 169-178.
51. Huan C, Jie S. (2013) The effect and mechanism of high-dose Ang II on the expression of ACE and ACE2 in vascular endothelial cells. Nanfang Medical University 2010 Grade, Master Dissertation.
52. Xu J, Yan P, Liu S. (2012) CGRP Protect HUVECs Injured by AngII and ERK1/2Signaling Pathway. Progress in Modern Biomedicine, 33: 6447-6527.